Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H1V8

UPID:
S6A17_HUMAN

ALTERNATIVE NAMES:
Sodium-dependent neurotransmitter transporter NTT4; Solute carrier family 6 member 17

ALTERNATIVE UPACC:
Q9H1V8; A6NEA8; A8K1R7; B9EIR5; Q5T5Q9

BACKGROUND:
SLC6A17, alternatively named Sodium-dependent neurotransmitter transporter NTT4, functions as a selective transporter for amino acids such as proline and glycine without the need for chloride. This distinct functionality sets it apart within the neurotransmitter transporter family.

THERAPEUTIC SIGNIFICANCE:
Linked to Intellectual developmental disorder, autosomal recessive 48, SLC6A17's involvement in neurological development and function makes it a compelling candidate for drug discovery efforts aimed at mitigating intellectual disability and associated symptoms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.